دورية أكاديمية
Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease.
| العنوان: | Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease. |
|---|---|
| المؤلفون: | Chopra HK; Senior Consultant, Department of Cardiology, Medanta Moolchand Heart Center, Delhi, India., Khullar D; Chairman, Nephrology and Renal Transplant Medicine, Dept. of Nephrology and Renal Transplant Medicine, Max Super-speciality Hospital, Delhi, India., Nair T; Head, Department of Cardiology, PRS Hospital, Trivandrum, Kerala, India., Wander GS; Professor, Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India., Ponde CK; Consultant Cardiologist and Head, Department of Cardiology, PD Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India., Ray S; Director, Department of Invasive Cardiology, AMRI Hospital, Kolkata, West Bengal, India., Nanda NC; Distinguished Professor of Medicine and Cardiovascular Disease, Division of Cardiology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Kasliwal RR; Chairman, Department of Clinical and Preventive Cardiology, Medanta-The Medicity, Gurugram, Haryana, India., Rana DS; Chairman, Department of Nephrology, Sir Ganga Ram Hospital, Delhi, India., Kirpalani A; Consultant Nephrologist, Bombay Hospital, Mumbai, Maharashtra, India., Sawhney J; Chief of Clinical and Preventive Cardiology, Chairman, Department of Cardiology, Sir Gangaram Hospital, Delhi, India., Chandra P; Chairman, Department of Interventional and Structural Heart Cardiology, Medanta-The Medicity, Gurgram, Haryana, India., Mehta Y; Director, Dept of Critical Care Medicine, Medanta Institute of Critical care Anaesthesiology, Medanta, The Medicity, Gurugram, Haryana, India., Kumar V; Principal Director and Chief of Cath Labs (Pan Max), Department of Cardiac Sciences, Max Hospital, Delhi, India., Tewari S; Professor of Cardiology at SGPGIMS, Lucknow, Uttar Pradesh, India., Pancholia AK; Head of Department, Department of Clinical and Preventive Cardiology, Arihant Hospital and Research Centre, Indore, Madhya Pradesh, India., Kher V; Chairman, Department of Nephrology, Department of Kidney Transplant, Epitome Kidney Urology Institute and Lions Hospital, Delhi, India., Bansal S; Consultant in Cardiology, Professor and Head, Department of Cardiology, Vardhaman Mahavir Medical College and Safdarjung Hospital, Delhi, India., Mittal S; Senior Cardiologist, Medanta-The Medicity, Gurugram, Haryana, India., Kerkar P; Senior Consultant Interventional Cardiologist, Asian Heart Institute, Mumbai, Maharashtra, India., Sahoo PK; Interventional Cardiology, Department of Cardiology, Apollo Hospital, Bhubaneshwar, Odisha, India., Hotchandani R; Consultant, Head, Department of Nephrology, Moolchand Centre for Renal Care and Dialysis, Moolchand Hospital, Delhi, India., Prakash S; Senior Director and Head, Department of Nephrology and Renal Transplantation, BLK-Max Super Speciality Hospital, Delhi, India., Chauhan N; Senior Cardiologist, Medanta-The Medicity, Gurugram, Haryana, India., Rastogi V; Director, Department of Interventional Cardiology, Head of Advanced Heart Failure Program, Fortis Escort Heart Institute, Delhi, India., Jabir A; Senior Cardiologist and Assistant Professor, Lisie Hospital, Cochin, Kerala, India., Shanmugasundaram S; Senior Cardiologist, Billroth Hospitals, Chennai, Tamil Nadu, India., Tiwaskar M; Consultant Physician and Diabetologist, Shilpa Medical Research Centre, Mumbai, Maharashtra, India., Sinha A; Senior Consultant, Department of Cardiology, Medanta Heart Institute, Patna, Bihar, India., Gupta V; Consulting Physician, Department of Internal Medicine, Kishori Ram Hospital and Diabetes Care Centre, Bhatinda, Punjab, India., Mishra SS; Director and Senior Consultant Cardiologist, Med N Heart Clinic, Cuttack, Odisha, India., Routray SN; Professor and Head, Department of Cardiology, SCB Medical College, Cuttack, Odisha, India., Omar AK; Director, Fortis Escorts Heart Institute, Department of Non-invasive Cardiology, Delhi, India., Swami OC; Sr. Vice President, Medical Services, Alembic Pharmaceuticals Ltd, Mumbai, Maharashtra, India, Corresponding Author., Jaswal A; Director, Department of Cardiac Pacing and Electrophysiology, Fortis Escorts Heart Institute, Delhi, India., Alam S; Consultant Interventional Cardiologist, Jayprabha Medanta Super Speciality Hospital, Patna, Bihar, India., Passey R; Consultant Cardiologist, Sir Ganga Ram Hospital, Delhi, India., Rajput R; Senior Consultant Cardiologist, Apollo Hospitals, Delhi, India., Paul J; Professor of Cardiology, Madras Medical College, Chennai, Tamil Nadu, India., Kapoor A; Head, Department of Cardiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India., Prabhakar D; Consultant Interventional Cardiologist, Ashwin Clinic, Chennai, Tamil Nadu, India., Chandra S; Chairman and Head, Dept. of Cardiology and Structural Heart Disease, BLK Max Superspeciality Hospital, Delhi, India., Malhotra P; Senior Professor, Cardiac Anaesthesia, All India Institute of Medical Sciences, Delhi, India., Singh VP; Sr. Consultant, Interventional Cardiologist, Fortis Escort Heart Institute, Delhi, India., Bansal M; Senior Cardiologist, Medanta-The Medicity, Gurugram, Haryana, India., Shah P; Assistant General Manager, Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, Maharashtra, India., Jain S; Associate Vice President, Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, Maharashtra, India., Bhargava M; Director of Cardiology and Interventional Cardiologist, Max Hospital, Delhi, India., Vijayalakshmi IB; Professor Emeritus, Former Head Pediatric Cardiology, Shri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, Karnataka, India., Varghaese K; Professor and Former Head, Department of Cardiology, St. John's Medical College, Bangalore, India., Jain D; Professor and Former Head, Department of Cardiology, IMS, BHU, Varanasi, Uttar Pradesh, India., Goel A; Director, Interventional Cardiology, Max Super-speciality Hospital, Delhi, India., Gaur N; CVTS, AIIMS Rishikesh, Rishikesh, Uttarakhand, India., Tandon R; Consultant, Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India., Moorthy A; Senior Consultant Cardiologist, SIMS Hospital, Chennai, Tamil Nadu, India., George S; Senior Interventional Cardiologist & Head of Cardiology, Department of Interventional Cardiology, Jubilee Memorial Hospital, Trivandrum, India., Katyal VK; Head of Dept. Department of General Medicine, Positron Hospital, Rohtak, Haryana, India., Mantri RR; Director, Department of Cardiology, Sir Ganga Ram Hospital, Delhi, India., Mehrotra R; Director and Head, Department of Non-Invasive Cardiology, Max Super Speciality Hospital, Delhi, India., Bhalla D; Senior Director, Department of Nephrology and Renal Transplant, Max Super Speciality Hospital, Delhi, India., Mittal V; Senior Consultant Diabetologist and Head, Centre for Diabetes and Metabolic Diseases, Heart and Lung Institute, Delhi, India., Rao S; Sr. Interventional Cardiologist, Director Cath Lab, Apollo Hospital, Indore, Madhya Pradesh, India., Jagia M; Director, Department of Anaesthesia and Critical care, Moolchand Hospital, Delhi, India., Singh H; Consultant, Critical Care Specialist, Max Super-speciality Hospital, Ghaziabad, Uttar Pradesh, India., Awasthi S; Consultant, Critical Care Specialist, Moolchand Hospital, Delhi, India., Sattur A; Director of Cath Lab HCG, Suchiraya Hospital, Hubli, Karnataka, India., Mishra R; Consultant Cardiologist, Indraprastha, Apollo Hospital, Delhi, India., Pandey A; Sr. Consultant Cardiologist, Department of Cardiology, Kailash Deepak Hospital, Delhi, India., Chawla R; Sr. Consultant Diabetologist and Director of North Delhi Diabetes and Cardiac Centre, Delhi, India., Jaggi S; Consultant Diabetologist and Head at Dr. Mohans Diabetes Specialities Centre, Delhi, India., Sehgal B; Sr. Consultant Nephrology, Shree Balaji Action Medical Institute, Delhi, India., Sehgal A; Head of Dept. and Chief Interventional Cardiologist, Yeshoda Superspeciality Hospital, Ghaziabad, Uttar Pradesh, India., Goel N; Director & HOD, Cardiology and HF Department, Fortis Shalimar Bagh Hospital, Delhi, India., Gupta R; Interventional Cardiologist, Max Superspeciality Hospital, Delhi, India., Kubba S; Director & Unit head, Department of Cardiology, Dharmshila Narayana Superspeciality Hospital, Delhi, India., Chhabra A; Interventional Cardiologist, Fortis Hospital, Delhi, India., Bagga S; Senior Cardiologist, Medanta-The Medicity, Gurugram, Haryana, India., Shastry NR; Consultant Cardiologist, Medanta Moolchand Heart Center, Delhi, India. |
| المصدر: | The Journal of the Association of Physicians of India [J Assoc Physicians India] 2024 May; Vol. 72 (5), pp. 77-88. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Association of Physicians of India Country of Publication: India NLM ID: 7505585 Publication Model: Print Cited Medium: Print ISSN: 0004-5772 (Print) Linking ISSN: 00045772 NLM ISO Abbreviation: J Assoc Physicians India Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Bombay : Association of Physicians of India Original Publication: Bombay [1953?]- |
| مواضيع طبية MeSH: | Renal Insufficiency, Chronic*/complications , Renal Insufficiency, Chronic*/drug therapy , Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use , Bisoprolol*/therapeutic use , Angiotensin Receptor Antagonists*/therapeutic use, Humans ; India/epidemiology ; Consensus ; Adrenergic beta-1 Receptor Antagonists/therapeutic use |
| مستخلص: | Chronic kidney disease (CKD) is a major contributor to morbidity and mortality in India. CKD often coexists with heart failure (HF), diabetes, and hypertension. All these comorbidities are risk factors for renal impairment. HF and CKD are pathophysiologically intertwined, and the deterioration of one can worsen the prognosis of the other. There is a need for safe renal pharmacological therapies that target both CKD and HF and are also useful in hypertension and diabetes. Neurohormonal activation achieved through the activation of the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS), and the natriuretic peptide system (NPS) is fundamental in the pathogenesis and progression of CKD and HF. Angiotensin receptor neprilysin inhibitor (ARNi), sodium-glucose cotransporter 2 inhibitors (SGLT-2i), and selective β1-blocker (B1B) bisoprolol suppress this neurohormonal activation. They also have many other cardiorenal benefits across a wide range of CKD patients with or without concomitant HF, diabetes, or hypertension. This consensus statement from India explores the place of ARNi, SGLT-2i, and bisoprolol in the management of CKD patients with or without HF and other comorbidities. (© Journal of the Association of Physicians of India 2024.) |
| المشرفين على المادة: | 0 (Sodium-Glucose Transporter 2 Inhibitors) Y41JS2NL6U (Bisoprolol) 0 (Angiotensin Receptor Antagonists) 0 (Adrenergic beta-1 Receptor Antagonists) |
| تواريخ الأحداث: | Date Created: 20240617 Date Completed: 20240617 Latest Revision: 20240617 |
| رمز التحديث: | 20240617 |
| DOI: | 10.59556/japi.72.0543 |
| PMID: | 38881115 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0004-5772 |
|---|---|
| DOI: | 10.59556/japi.72.0543 |